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Summary
The development of antibodies against infused factor VIII (FVIII) in patients with haemophilia A 
is a serious complication leading to poorly controlled bleeding and increased morbidity. No 
treatment has been proven to reduce high titre antibodies in patients who fail immune tolerance 
induction or are not candidates for it. The Rituximab for the Treatment of Inhibitors in Congenital 
Hemophilia A (RICH) study was a phase II trial to assess whether rituximab can reduce 
anamnestic FVIII antibody (inhibitor) titres. Male subjects with severe congenital haemophilia A 
and an inhibitor titre ≥5 Bethesda Units/mL (BU) following a FVIII challenge infusion received 
rituximab 375 mg/m2 weekly for weeks 1 through 4. Post-rituximab inhibitor titres were measured 
monthly from week 6 through week 22 to assess treatment response. Of sixteen subjects who 
received at least one dose of rituximab, three (18.8%) met the criteria for a major response, 
defined as a fall in inhibitor titre to <5 BU, persisting after FVIII re-challenge. One subject had a 
minor response, defined as a fall in inhibitor titre to <5 BU, increasing to 5–10 BU after FVIII re-
challenge, but <50% of the original peak inhibitor titre. Rituximab is useful in lowering inhibitor 
levels in patients, but its effect as a solo treatment strategy is modest. Future studies are indicated 
to determine the role of rituximab as an adjunctive therapy in immune tolerisation strategies.
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INTRODUCTION
For many patients with congenital haemophilia A, the genetic absence or dysfunction of the 
Factor VIII (FVIII) protein causes an immune response to infused FVIII replacement 
therapy. High titre alloreactive FVIII antibodies, or inhibitors, that neutralize the function of 
infused FVIII develop in as many as 30–40% of patients with severe haemophilia A,[1–2] 
and up to 13% of those with mild or moderate haemophilia A.[3]
Treatment of bleeding in patients with high titre inhibitors is difficult. The major therapeutic 
modalities consist of agents that bypass the need for Factor VIII, such as prothrombin 
complex or recombinant Factor VIIa concentrates. However, neither of these therapies leads 
to the predictable and effective hemostasis provided by Factor VIII replacement therapy. 
Patients with persistent inhibitors thus suffer consequences of serious, poorly controlled 
bleeding, which often leads to restrictive joint disease, prolonged hospitalizations, and in 
some cases, early death.[4–7]
The only approach that has been shown to eradicate inhibitors in patients with congenital 
haemophilia is immune tolerance induction (ITI) therapy which involves regular (usually 
daily) exposure to FVIII concentrates to promote immunologic acceptance of the FVIII 
protein.[8] ITI is almost always indicated as first line treatment in patients who have had an 
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inhibitor for less than a year. However, a significant portion (up to 50%) of patients will fail 
ITI, resulting in the presence of permanent inhibitors.[9–12] In addition, patients with long 
standing inhibitors are not usually considered candidates for ITI because inhibitors present 
for longer than a year are typically refractory to ITI, and because older age at ITI initiation 
reduces ITI success.[10] Ultimately, as many as 15–20% of these patients have permanent 
life-long inhibitors.
Rituximab (Rituxan®) is a genetically engineered chimeric murine/human monoclonal 
antibody directed against the CD20 antigen. At a dose of 375mg/m2 weekly × 4 weeks, 
circulating B cells are depleted within the first one to three doses with sustained depletion 
for up to 6–9 months. B-cell recovery begins at approximately 6 months following 
completion of treatment. Median B-cell levels return to normal by 12 months following 
completion of treatment.[13] Due to its profound effect on circulating B lymphocytes, 
rituximab has been used to successfully treat a variety of autoimmune disorders,[14–18] 
including acquired haemophilia due to autoantibodies directed against FVIII.[19–22] 
Anecdotal reports have suggested that rituximab may also have benefit in the management 
of FVIII alloantibodies (inhibitors) in patients with congenital haemophilia A.[23–25]
The purpose of the RICH study was to determine if rituximab given in 4 weekly doses could 
reduce the titre and anamnestic response of FVIII inhibitors following exposure to infused 
FVIII in patients with severe congenital haemophilia A who have high-responding 
inhibitors.
MATERIALS AND METHODS
Study Development and Oversight
The Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (RICH) Study 
was designed by members of the Haemophilia Subcommittee of the Transfusion Medicine/
Hemostasis (TMH) Clinical Trials Network as a proof-of-concept trial to determine whether 
four weeks of rituximab treatment could significantly reduce or eliminate high titre 
inhibitors in patients with severe haemophilia A. The protocol, which was registered at 
ClinicalTrials.gov as NCT00331006 and under IND BB-12417 for off-label study of 
rituximab, was opened at 13 sites in the United States, each of which obtained approval from 
an Institutional Review Board. All adults enrolled provided written informed consent; 
consent for children was obtained from a parent or legal guardian. Assent was provided by 
children where required by local policy. Central laboratory testing for inhibitor titres was 
performed at Orthopaedic Hospital Special Coagulation Laboratory (Los Angeles, CA). 
Central data coordination was performed by the TMH Network Data Coordinating Center 
(DCC) at New England Research Institutes. TMH was funded by grants from the National 
Heart, Lung, and Blood Institute (NHLBI). A data and safety monitoring board (DSMB), 
established by NHLBI, regularly reviewed the data including accrual, study endpoints, and 
adverse events.
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Patients were eligible for inclusion in the study if they had severe congenital haemophilia A, 
were at least 18 months of age, and had a documented historical FVIII inhibitor titre ≥5 
Bethesda Units/mL (BU). The first detection of an inhibitor titre ≥5 BU had to be at least 12 
months prior to the initial screening visit unless the patient had failed ITI. Patients were 
excluded from the study if they were undergoing ITI; had received FVIII concentrate within 
7 days prior to the initial screening visit or were expected to use FVIII concentrate for the 
treatment of bleeds; had received immunomodulatory drugs within 30 days prior to the 
initial screening visit; had previously received rituximab; or were currently participating in 
trials of investigational therapies for haemophilia. Patients were also excluded if they were 
HIV positive or had any of the following: an immune deficiency disorder; liver disease 
defined by serum alanine transaminase (ALT) or aspartate aminotransferase (AST) greater 
than three times the upper limit of normal, albumin <2.5 g/dL and/or international 
normalized ratio (INR) >1.7; evidence of hepatitis B infection; a history of cardiac 
arrhythmias, renal insufficiency, or pulmonary infiltrates; active febrile illness; or known 
allergies to murine or humanized antibodies.
Study Design
The RICH study was a single-arm, open-label, phase II clinical trial of 4 weekly doses of 
rituximab. The study had four phases: Screening Phase, Treatment Phase, Follow-up Phase I, 
and Follow-up Phase II (Figure 1).
Screening Phase—Patients meeting the eligibility criteria received a challenge infusion 
of FVIII at a dose of 50 IU/kg. A post-challenge Factor VIII inhibitor titre sample was 
drawn after 5–7 days; if this titre was ≥5 BU, the patient was eligible to enter the treatment 
phase of study. If the titre was <5 BU, another sample was drawn after an additional 5–7 
days, and if the second post-challenge inhibitor titre was ≥5 BU, the patient entered the 
treatment phase of the study. If the inhibitor titre remained <5 BU, the patient was deemed 
ineligible to proceed to the treatment phase and study participation ended.
Treatment Phase—Rituximab treatment was initiated 5–9 days following the day that the 
treatment-qualifying post-challenge inhibitor titre sample was drawn. Patients received 
rituximab 375 mg/m2 intravenously once per week for 4 weeks. Inhibitor titre samples were 
obtained immediately prior to the first and fourth infusion of rituximab.
Follow-up Phase I (Efficacy Phase)—During Follow-up Phase I, inhibitor titre samples 
were obtained every four weeks, beginning at week 6 (2 weeks after the fourth rituximab 
dose) and continuing through week 22. The first time an inhibitor titre was found to be <5 
BU during Follow-up Phase I, the subject was re-challenged with Factor VIII 50 IU/kg, and 
an inhibitor titre sample was measured 5–7 days after this Factor VIII re-challenge.
Follow-Up Phase II (Safety Phase)—Patients continued to be followed beyond week 22 
for long-term safety. Patients were monitored clinically at weeks 36, 52 and 100. Factor VIII 
inhibitor titres were determined at the week 36 and week 52 study visits for patients whose 
titre fell below 5 BU during Follow-Up Phase I, and at the week 100 study visit from all 
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subjects. During weeks 64, 76 and 88, patients were contacted via telephone questionnaire to 
obtain information on infections, adverse events, and concomitant medications.
Study Outcomes
Because RICH was designed to investigate the possible efficacy and safety of rituximab, all 
study outcomes were to be assessed in subjects who received at least one dose of rituximab. 
All study measurements of inhibitor titres were carried out at the central laboratory.
RICH was designed as a proof-of-concept study. The primary efficacy outcome was the 
proportion of subjects who had a major response. A major response was defined to occur 
when a patient’s FVIII inhibitor titre fell to <5 BU during Follow-Up Phase I and remained 
<5 BU following the re-challenge with FVIII. The definition of a major response did not 
require a complete eradication of the inhibitor. However, if rituximab was shown to be 
successful in reducing inhibitor titres and anamnestic response to FVIII, it is possible that 
some patients who previously could not be treated with FVIII might be able to receive FVIII 
treatment or prophylaxis.
The secondary efficacy outcome was the proportion of subjects who had either a major or 
minor response. A minor response was defined to occur when a patient’s inhibitor titre fell 
to <5 BU during Follow-Up Phase I, and the inhibitor titre obtained 5–7 days following the 
re-challenge with FVIII was both between 5–10 BU and less than 50% of the treatment-
qualifying inhibitor titre measured following the initial FVIII challenge.
Patients who did not achieve a FVIII inhibitor titre of <5 BU during Follow-Up Phase I were 
deemed to be non-responders. In addition, patients who achieved a FVIII inhibitor titre of <5 
BU during Follow-Up Phase I, but who on re-challenge with FVIII had an inhibitor titre that 
was either >10 BU or ≥50% of their treatment-qualifying inhibitor titre or both, were also 
deemed to be non-responders. The protocol specified that all subjects who received at least 
one dose of rituximab and did not have data to determine whether a major or minor response 
occurred were considered non-responders.
Statistical Considerations
Sample size—Because it is very unlikely that an immunocompetent subject with a high 
titre inhibitor would have a spontaneous fall in inhibitor titre below 5 BU, and remain below 
5 BU after re-challenge with FVIII, the null hypothesis was that the true probability that a 
subject would meet the criteria for major response was ≤5% (i.e. P0=0.05). The primary 
analysis of the primary outcome was to determine the probability of achieving at least the 
observed number of major responses, if the null hypothesis were true. If this probability was 
<0.05, the null hypothesis would be rejected. Because even a modest probability of major 
response could indicate that rituximab was a promising approach to inhibitor treatment, the 
study was designed to have 90% power to reject the null hypothesis if the true probability of 
a major response was at least 20% (i.e. P1=0.20). Assuming that up to 10% of subjects who 
received at least one dose of rituximab would be lost to follow-up before endpoint data were 
obtained, and considering those lost to follow-up as not having a major response, for 
purposes of sample size calculation P0 and P1 were reduced to 0.045 and 0.18, respectively. 
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To achieve 90% power, the study planned to enrol 43 subjects who received at least one dose 
of rituximab (Hintze J. PASS 2008. NCSS, LLC. Kaysville, Utah. www.ncss.com). It was 
estimated that approximately 50 subjects would need to be enrolled to obtain 43 subjects 
who qualified for rituximab treatment.
Statistical analyses were performed using SAS (SAS/STAT Software, version 9.3. Cary, NC: 
SAS Institute; 2002–2010). In addition to the primary analysis of the primary outcome, two-
sided exact binomial confidence intervals for the proportion of subjects with a major 
response, and the proportion of subjects with either a major or minor response, were 
calculated. To assess safety, data on the number and types of bleeding events, and other 
serious adverse events (SAEs) and non-serious adverse events (AEs) were tabulated. 
Comparisons between subjects whose post-challenge inhibitor titres were at least 5 BU vs. 
less than 5 BU were made using Fisher’s Exact test for binary or categorical variables, and 
the non-parametric Wilcoxon rank sum test for continuous variables. Similar analyses 
compared rituximab-treated subjects who achieved at least a minor response vs. rituximab-
treated subjects who were considered non-responders. For each such comparison, all 
subjects with available data were analysed.
Stopping guidelines are detailed in the Supplementary Appendix.
RESULTS
Study enrolment began in August 2006. The DSMB recommended in November 2010 that 
the study close to new enrolment due to the low accrual rate. Figure 2 shows the flow of 
subjects through the study. Twenty-three male patients were enrolled. The median age of 
enrolled subjects was 13.7 years (range 2.9 – 60.2 years). Of the 23 enrolled patients, 21 
received the initial challenge with Factor VIII. The two patients who were not challenged 
included one patient who was lost to follow-up prior to receiving the initial FVIII challenge 
and a second patient who was unable to receive the initial challenge because the study was 
closed before he received the FVIII challenge. One additional patient withdrew from the 
study after receiving the initial FVIII challenge but before eligibility for the treatment phase 
was determined. Of the 20 patients who received an initial FVIII challenge and subsequent 
inhibitor titre determination, 16 (80%) had a post-challenge titre ≥5 BU and qualified for the 
rituximab treatment phase of the study. Post-challenge peak inhibitor titres for the four non-
qualifying subjects ranged between 1.8 and 2.5 (Supplemental Figures 1A–D). 
Characteristics for the 16 subjects with post-challenge titres qualifying them for the 
Treatment Phase and the 4 subjects with non-qualifying post-challenge titres are shown in 
Table 1. The 16 subjects who qualified for treatment had significantly higher pre-challenge 
inhibitor titre than the 4 subjects who did not qualify for treatment (median 9.6 BU vs. 1.8 
BU for qualifiers and non-qualifiers, respectively; p=0.04).
All 16 patients who qualified for the rituximab treatment phase of the study received at least 
one rituximab treatment and are included in the analyses of efficacy and safety. One subject 
received only one partial rituximab infusion, which was stopped due to hypotension. The 
patient subsequently withdrew from the study and did not receive any further doses of 
rituximab. Of the remaining 15 patients, 14 patients received four complete infusions and 1 
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received three complete infusions and one partial infusion. Among these 15 patients, one 
subject was lost to follow-up after the Week 18 visit, one was lost to follow-up after the 
Week 36 visit and two subjects were lost to follow-up after the Week 52 visit.
Efficacy
Five patients (31.25% of those treated with rituximab) had an inhibitor titre <5 BU during 
Follow-Up Phase I. Four of these patients received a re-challenge with Factor VIII. The fifth 
patient’s clinical team began treating him with daily infusions of FVIII (200 IU/kg/day) 
following the week 22 visit but before the central laboratory inhibitor titre result for week 22 
(4.5 BU) was known. Therefore, a post-treatment challenge was deemed clinically 
inappropriate for this patient, and he was considered a non-responder per protocol 
guidelines.
Three patients (18.75% of those treated with rituximab) had a major response. The exact 
binomial probability of observing at least 3 major responders in 16 subjects, if the true major 
response rate is 5%, is 0.043, therefore rejecting the null hypothesis that the major response 
rate is ≤5%. Due to the small sample size, the two-sided 95% exact binomial confidence 
interval for this percentage is wide, 4.05% – 45.65%.
There were 4 patients who had either a major or minor response (25.00%, 95% exact 
binomial confidence interval 7.27% – 52.38%). Inhibitor titres measured after the initial and 
post-treatment FVIII challenges for the four subjects who achieved a major or minor 
response are shown in Table 2 and Figures 3A–D. After the initial FVIII challenge, peak 
inhibitor titres for these subjects ranged between 6.0 and 12.4 BU, and after the post-
treatment challenge, titres ranged between 1.5 and 5.5 BU. The average absolute decrease 
was 5.2 BU and the average percentage change in BU was a decrease of 60.8%.
Although the RICH study did not collect systematic data on the use of FVIII after a subject 
had a response, three of the four subjects who met the criteria for a major or minor response 
are known to have received at least some FVIII after achieving a response. Two subjects 
(Figures 3B and 3D) were reported to have received FVIII prophylactically beginning 
approximately 1 month after the FVIII re-challenge. Inhibitor titres for the major responder 
in Figure 3B remained below 5 BU through his month 24 visit, approximately 21 months 
after achieving his response, The minor responder (Figure 3D) had inhibitor titres that 
remained just over 5 BU throughout his remaining time on study, approximately 7 months 
after achieving his response. The third subject (Figure 3C) known to have used Factor VIII 
prophylactically after achieving a response experienced a steady rise in inhibitor titres after 
the FVIII post-treatment challenge, rising to approximately 15 BU by the month 24 visit. 
This subject was reported to have received FVIII prophylactically beginning six weeks after 
the FVIII re-challenge. In addition, this subject also received FVIII for the treatment of 
bleeding events reported during the last study visit.
Inhibitor titres over time for the 12 subjects who qualified for rituximab treatment but were 
not classified as having a major or minor response are shown in Supplementary Figures 2A–
L. Supplemental Figure 2D corresponds to the subject who qualified for the re-challenge but 
did not receive it.
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Characteristics for the 4 subjects who had either a major or minor response to rituximab and 
the 12 subjects who were non-responders are shown in Table 3. The 4 subjects who achieved 
at least a minor response were significantly older when the inhibitor to FVIII was first 
detected than the 12 subjects who were non-responders (median 7.2 years vs. 1.5 years for 
responders and non-responders, respectively; p=0.03).
Safety
Table 4 shows the types and frequencies of the SAEs and other AEs that were reported 
during the study. Among the 16 subjects who received at least one dose of rituximab, 574 
adverse events (both serious and non-serious) were reported, and 15 subjects (94%) had at 
least one adverse event. Among all adverse events, 47 events (8%) met SAE criteria and 11 
subjects (69%) experienced at least one SAE. An additional 527 AEs did not meet SAE 
criteria. These 527 AEs occurred in 15 subjects.
Of all adverse events, 459 (80%) events occurring among 15 subjects were classified as 
bleeding events. Among these bleeding adverse events, 31 (7%) met SAE criteria and 9 
subjects experienced at least one such bleeding SAE.
The remaining 115 (20%) adverse events were classified as non-bleeding adverse events and 
were reported among 13 subjects. Sixteen (14%) of the non-bleeding adverse events met 
SAE criteria and 10 subjects experienced at least one such non-bleeding SAE. All non-
bleeding SAEs resolved by the time the subject ended RICH participation (13 with no 
sequelae and 3 with sequelae). Nearly all the other non-bleeding AEs also resolved (94 
without sequelae and 1 with sequelae), but 3 were ongoing at the end of study participation 
and the final status of one non-bleeding AE was unknown. There were no deaths among 
study participants.
DISCUSSION
Rituximab has previously demonstrated efficacy in treating autoimmune disorders, leading 
to clinical benefit by reducing or eliminating pathological autoantibodies.[14–18] However, 
its ability to suppress alloantibodies has not been clearly demonstrated. Numerous reports 
have indicated that rituximab is effective in eradicating Factor VIII autoantibodies and it is 
now considered a major treatment strategy for patients with acquired haemophilia A.[19–22] 
Given the success in treating autoreactive FVIII inhibitors, there were early attempts to use 
rituximab as an adjunctive agent in ITI regimens that were designed to eradicate inhibitors in 
patients with congenital haemophilia, particularly in patients who had failed to achieve 
tolerance with standard ITI.[26–30] Several reports and one larger cohort study[31] 
suggested that rituximab augmented the efficacy of ITI in some patients and led to 
tolerisation in some individuals who appeared to be resistant to standard ITI. In addition 
there have been a few case reports of successful inhibitor eradication in patients who 
received rituximab without concomitant ITI, although the follow-up of these patients was 
limited.[32] In patients where tolerance is not achieved, lowering the inhibitor using 
rituximab may decrease bleeding frequency, especially in patients with mild or moderate 
haemophilia.[33]
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For patients who have failed ITI therapy or who are not candidates for ITI, persistence of 
inhibitors greatly increases morbidity and treatment costs.[34–36] Given the disease burden, 
physical morbidity, psychosocial impact, and financial cost, there has been a rapid escalation 
of rituximab use as a potentially effective treatment modality, despite a lack of clear 
evidence of benefit. Rituximab has potential side-effects that include complications from 
immune suppression such as serious opportunistic infections [35–36]; in addition, the long-
term effects on children are unclear.
The problem in understanding the potential benefit of rituximab in earlier reports is that it is 
difficult to assess whether its addition to ongoing ITI contributed to ITI success since it is 
possible that simply continuing ITI without rituximab may have resulted in the same good 
outcome. In those rare cases where lowering or eliminating a FVIII inhibitor was ascribed to 
rituximab as a single agent (without concomitant ITI), it is unclear if this response was 
maintained after re-exposure to FVIII. High titre inhibitors in congenital haemophilia A are 
immunologically anamnestic and may disappear over time as long as there is no exposure to 
FVIII, but will usually reappear upon further exposure to FVIII. In the case reports of 
inhibitor eradication, it was often unclear whether the patient subsequently received re-
exposure to FVIII and demonstrated that the anamnestic immunologic response was truly 
abated by rituximab therapy.
The RICH Study was the first prospective clinical trial designed to measure the effect of 
rituximab on reducing the anamnestic immune response against Factor VIII in patients with 
inhibitors, which we deemed a more definitive assessment of rituximab efficacy than simply 
observing decreasing inhibitor titres after its use. This Phase II study was a proof of 
principle study to determine whether the safety and efficacy of rituximab would justify its 
inclusion in a larger, definitive study in which it would be combined with ITI for inhibitor 
eradication. Even though the definition of a major response used in RICH did not require the 
eradication of the inhibitor, three of the four patients who achieved at least a minor response 
were treated with FVIII prophylactically after achieving a response, per the discretion of the 
treating physician. Two of these subjects had titres that remained low after the initiation of 
FVIII prophylaxis. The RICH results indicate that there is evidence for a modest benefit of 
rituximab as a single agent to reduce the immune response to FVIII in some patients.
Rituximab reduced the anamnestic inhibitor rise in 4 of 16 subjects (25%), who were 
considered treatment responders. Responders, compared to non-responders, were older at the 
time of inhibitor development (7.2 compared to 1.5 years), but showed no difference in 
duration of inhibitor or historical peak inhibitor titre. A fifth subject, whose inhibitor 
declined to less than 5 BU, met the criteria for a FVIII re-challenge dose, but was placed on 
FVIII therapy without receiving the FVIII challenge for the primary study endpoint.
All responders had a baseline inhibitor level <12 BU, suggesting that rituximab may be 
more effective when inhibitor levels are not high at the time of treatment initiation. A similar 
observation has been made with respect to ITI where a lower baseline inhibitor titre at ITI 
initiation predicts a higher likelihood of achieving tolerance.[10] Responders also had 
somewhat lower levels of CD4+ and CD20+ lymphocyte populations and Immunoglobulin 
M (IgM) at study baseline, but these comparisons did not reach statistical significance.
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There were no major safety concerns with rituximab in this patient population. The majority 
of adverse events were bleeding events, as expected in this patient population. While there 
were some non-serious ALT elevations, no clinical liver disease was reported.
One unexpected observation was that 4 of the 20 subjects who received the initial FVIII 
challenge and had a subsequent inhibitor titre determination did not experience an 
anamnestic rise in their inhibitor titre after exposure to FVIII, and were thus ineligible to 
proceed to rituximab therapy. This group was similar to the group that did have a post-
challenge titre >5 BU, except that their pre-challenge inhibitor titre was lower. At least 3 of 
the 4 had historical inhibitor peak titres >50 BU and all were being managed as chronic 
high-responder inhibitor patients. Although 2 of the 4 had a known history of undergoing 
ITI in the past, they had been deemed ITI failures; all 4 were being treated with bypassing 
therapy for bleeding. Nevertheless, all 4 behaved as low-titre, low-responder inhibitor 
patients, with inhibitor titres not going above 2.5 BU after FVIII exposure. This raises the 
possibility that some high responding inhibitor patients may, over time, lose immunologic 
anamnesis and be candidates for management with FVIII replacement therapy. These 
observations should perhaps prompt an occasional FVIII challenge for longstanding 
inhibitor patients whose current inhibitor titres are <5 BU, to identify those who may benefit 
from returning to FVIII replacement therapy.
The study had several limitations. The sample size was small due to the rarity of inhibitor 
patients who met the study criteria, and the difficulty in recruiting among this rare disease 
population. In addition, the study was a phase II, non-randomized trial which was developed 
as a pilot study, due to the difficulty in conducting large scale randomized clinical trials in 
this patient population. The duration of response to rituximab as a single agent is also a 
concern since it is clear that rituximab-induced reduction in circulating CD20 lymphocytes 
lasts 6–9 months, although longer term clinical responses are seen in patients with 
autoimmune disorders. However, given the characteristics of our patient population, we 
expect that these results may be generalizable to patients with a history of high titre 
inhibitors who have failed ITI or who are not candidates for ITI.
Despite its limitations, the RICH Study demonstrates that as many as 25% of patients with 
alloantibody inhibitors to FVIII achieved some benefit from rituximab as a single agent. 
While this benefit is modest, it nevertheless points to demonstrable efficacy and supports 
further study of rituximab as an adjunctive therapy in immune tolerance regimens.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. RICH Study Schema
A) Screening phase, B) Treatment and follow-up phase (by week on study following 
screening phase).
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Figure 2. RICH Study Population
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Figure 3. Inhibitor titre results among subjects who responded, by subject
Solid diamond represents date of FVIII re-challenge. A) major responder 1, B) major 
responder 2, C) major responder 3, D) minor responder 1.
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Table 1
Comparison of Selected Variables Between Subjects Who Qualified For Rituximab Treatment and Those Who 





Baseline Demographic/Laboratory Test Median (Range) Median (Range) P value
AGE (years) 14.2 (4.2 – 38.2) 14.4 (10.6 – 18.0) 0.82
WEIGHT (kg) 48.2 (15.6 – 78.1) 64.2 (48.4 – 99.7) 0.16
HEIGHT (cm) 158.0 (102.0 – 184.0) 164.5 (145.5 – 169.0) 0.93
ETHNIC ORIGIN
 • HISPANIC 4 (25%) 0 (0%) 0.54
RACE
 • BLACK/AFRICAN AMERICAN 3 (19%) 2 (50%) 0.25
 • WHITE 13 (81%) 2 (50%)
AGE AT FIRST EXPOSURE TO FVIII (months)a 1.5 (0.0 – 43.0) 7.0 (7.0 – 7.0) 0.34
AGE INHIBITOR FIRST DETECTED (years)b 2.3 (0.3 – 11.0) 0.9 (0.5 – 1.4) 0.20
DURATION OF INHIBITOR (years)b 10.3 (0.6 – 34.4) 14.6 (11.6 – 17.6) 0.37
HISTORICAL PEAK INHIBITOR TITRE (BU)c 235.0 (33.3 – 4096.0) 115.0 (55.0 – 288.0) 0.35
HISTORY OF IMMUNE TOLERANCE INDUCTIONc 13 (81%) 2 (67%) 0.53
 • DURATION OF IMMUNE TOLERANCE INDUCTION (years)d 1.0 (0.01 – 2.9) 5.2 (5.2 – 5.2) 0.19
BASELINE INHIBITOR TITRE (BU) MEASURED PRIOR TO INITIAL FVIII 
INFUSION 9.6 (0.5 – 730.0) 1.8 (0.8 – 4.0) 0.04
ALT (units/L) 25.0 (6.0 – 49.0) 19.0 (17.0 – 24.0) 0.61
AST (units/L) 23.5 (15.0 – 52.0) 29.5 (20.0 – 33.0) 0.68
WBC (103/μL) 6.5 (3.3 – 11.1) 5.7 (4.6 – 5.9) 0.16
ABSOLUTE NEUTROPHIL COUNT (103/μL)e 4.1 (1.1 – 8.8) 2.4 (1.5 – 3.0) 0.18
ABSOLUTE LYMPHOCYTE COUNT (103/μL) 2.1 (1.1 – 4.2) 2.2 (2.0 – 2.6) 0.61
 • CD3 (103/mL) 1407 (661 – 3221) 1602 (1436 – 1706) 0.61
 • CD4 (103/mL) 916 (410 – 1915) 965 (754 – 1056) 0.74
 • CD8 (103/mL) 539 (182 – 1059) 496 (366 – 551) 0.64
 • CD19 (103/mL) f 353 (64 – 748) 457 (412 – 963) 0.27
 • CD20 (103/mL)f 316 (8 – 861) 457 (407 – 960) 0.14
IMMUNOGLOBULIN G (mg/dL) 1060 (847 – 1740) 1122 (891 – 1188) 0.74
IMMUNOGLOBULIN M (mg/dL) 120 (53 – 162) 89 (73 – 115) 0.12
Post-Baseline Laboratory Test
PEAK INHIBITOR TITRE FOLLOWING INITIAL FVIII CHALLENGE (BU)g 12.2 (5.5 – 1380.0) 2.0 (1.8 – 2.5) N/A
a
Data missing for 1qualifier. Data unknown for 5 qualifiers and 2 non-qualifiers
b
Data unknown for 2 non-qualifiers
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c
Data unknown for 1 non-qualifier
d
Among those with known history of ITI. Data unknown for 2 qualifiers and 1 non-qualifier. Data missing for 1 qualifier.
e
Additional lab test required by the study beginning April 6, 2007. Not required for 5 qualifiers and 1 non-qualifier
f
Data missing for one qualifier.
g
Computed as the maximum inhibitor titre obtained at Visit 3 or 3A. No p-value computed because this titre was used to determine whether a 
subject was a qualifier.
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Table 3
Comparison of Selected Variables Between Rituximab-Treated Subjects Who Achieved at Least a Minor 





Baseline Demographic/Laboratory Test Median (Range) Median (Range) P value
AGE (years) 15.2 (11.5 – 17.2) 13.2 (4.2 – 38.2) 0.68
WEIGHT (kg) 68.6 (37.8 – 78.1) 36.2 (15.6 – 77.9) 0.12
HEIGHT (cm) 167.8 (144.5 – 184.0) 150.5 (102.0 – 175.0) 0.32
ETHNIC ORIGIN
 • HISPANIC 0 (0%) 4 (33%) 0.52
RACE






AGE AT FIRST EXPOSURE TO FVIII (months)a 3.5 (0.0 – 7.0) 1.5 (0.0 – 43.0) 1.00
AGE INHIBITOR FIRST DETECTED (years) 7.2 (3.3 – 11.0) 1.5 (0.3 – 7.5) 0.03
DURATION OF INHIBITOR (years) 8.0 (0.6 – 13.9) 11.5 (2.8 – 34.4) 0.44
HISTORICAL PEAK INHIBITOR TITRE (BU) 216.5 (64.0 – 235.0) 661.0 (33.3 – 4096.0) 0.29
HISTORY OF IMMUNE TOLERANCE INDUCTION 4 (100%) 9 (75%) 0.53
 • DURATION OF IMMUNE TOLERANCE INDUCTION (years)b 0.4 (0.01 – 0.8) 1.7 (0.4 – 2.9) 0.18
BASELINE INHIBITOR TITRE (BU) MEASURED PRIOR TO INITIAL FVIII 
INFUSION 7.8 (2.8 – 10.3) 11.9 (0.5 – 730.0) 0.27
ALT (units/L) 20.5 (13.0 – 34.0) 28.0 (6.0 – 49.0) 0.68
AST (units/L) 20.5 (18.0 – 34.0) 24.5 (15.0 – 52.0) 0.38
WBC (103/μL) 6.6 (3.3 – 7.0) 6.5 (3.8 – 11.1) 0.68
ABSOLUTE NEUTROPHIL COUNT (103/μL)c 3.1 (1.1 – 5.2) 4.2 (1.4 – 8.8) 0.49
ABSOLUTE LYMPHOCYTE COUNT (103/μL) 1.8 (1.1 – 2.8) 2.1 (1.6 – 4.2) 0.38
 • CD3 (103/mL) 1068 (661 – 1734) 1514 (949 – 3221) 0.15
 • CD4 (103/mL) 555 (410 – 929) 985 (432 – 1915) 0.08
 • CD8 (103/mL) 456 (182 – 565) 563 (347 – 1059) 0.32
 • CD19 (103/mL)d 446 (299 – 620) 332 (64 –- 748) 0.48
 • CD20 (103/mL)d 165 (8 – 525) 338 (9 – 861) 0.29
IMMUNOGLOBULIN G (mg/dL) 1134 (1000 –1579) 1060 (847 – 1740) 0.91
IMMUNOGLOBULIN M (mg/dL) 108 (59 – 111) 126 (53 – 162) 0.06
Post-Baseline Laboratory Tests
PEAK INHIBITOR TITRE FOLLOWING INITIAL FVIII CHALLENGE (BU)e 7.7 (6.0 – 12.4) 20.0 (5.5 – 1380.0) 0.24
INHIBITOR TITRE (BU) AT VISIT 12 3.3 (1.2 – 4.6) 23.5 (4.5 – 1577.0) 0.02
INHIBITOR TITRE (BU) AT VISIT 15 7.9 (0.8 – 15.0) 17.0 (0.0 – 325.0) 0.43
NADIR CD19 COUNT (103/mL) BETWEEN VISITS 7 AND 12 (INCLUSIVE)f 0.000 (0.000, 0.000) 0.001 (0.000, 0.069) 0.11
a
Data unknown for 2 responders and 3 non-responders, missing for 1 non-responder
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b
Among those with known history of ITI. Data unknown for 2 responders. Data missing for 1 non-responder.
c
Additional lab test required by the study beginning April 6, 2007. Not required for 1 responder and 4 non-responders
d
Data missing for one non-responder
e
Computed as the maximum inhibitor titre obtained at Visit 3 or 3A.
f
CD19 measurements were scheduled to occur at Visits, 7, 10 and 12 and immediately before the FVIII re-challenge, if any. One non-responder did 
not have any CD19 counts during this time frame because he withdrew after Visit 4. A second non-responder did not have a CD19 at Visit 12 
because he was lost to follow-up after Visit 11. Four additional non-responders had a Visit 12 but did not have CD19 counts reported from the visit. 
One other non-responder did not have CD19 counts reported at Visits 10 or 12.
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